Lv1
22 积分 2024-07-09 加入
Optimizing adjuvant treatment strategy in advanced clear cell endometrial cancer: systematic review and meta-analysis
5天前
已关闭
Unveiling Commonalities: Exploring Shared Characteristics in Clear-Cell Carcinomas of the Gynecologic Tract
5天前
已完结
B7-H4 in cancer immune evasion and immunotherapy
3个月前
已完结
Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancer
3个月前
已关闭
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
4个月前
已完结
HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications
4个月前
已关闭
Endometriosis and ovarian cancer: epidemiological evidence, molecular insights, and clinical decision-making
5个月前
已关闭
ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer
5个月前
已完结
Guideline for the management pathway and quality control of ovarian cancer diagnosis and treatment in county-level regions of China (2025 Edition)
6个月前
已关闭
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
6个月前
已完结
皖公网安备34019202002308
